DARTMOUTH, Nova Scotia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial Officer Pierre Labbé will
present a corporate update at the Annual Piper Jaffray Healthcare Conference, which takes place from November 27–29 in New York, NY.
IMV’s presentation details include:
The webcast will be archived for 90 days following the live presentation. A copy of the presentation will also be available on
the Events, Webcasts &
Presentations page of IMV’s website: www.imv-inc.com.
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy
more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is
pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology
leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating
immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a
combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
Contacts for IMV:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
